Introduction
The platelet P2Y 12 adenosine diphosphate receptor inhibitor clopidogrel is widely used to reduce blood clotting in patients at high risk for vascular thrombotic events. Due to its complex pharmacokinetic profile, clopidogrel is susceptible to various drug-drug interactions and genetic polymorphisms resulting in variable drug response (Mega et al., 2009; Floyd et al., 2012; Frelinger et al., 2012; Tornio et al., 2014; Tarkiainen et al., 2015) . Clopidogrel is a prodrug that is metabolized via two distinct routes. Approximately 10% of the absorbed dose undergoes a two-step oxidative metabolism pathway, producing the active cis 5-thiol metabolite, while the majority of the dose is metabolized by sequential hydrolysis and conjugation reactions into pharmacodynamically inactive clopidogrel carboxylic acid and clopidogrel acyl-β-D-glucuronide (Savi et al., 2000; Tang et al., 2006; Hagihara et al., 2009; Silvestro et al., 2011) (Figure 1 ).
The oxidative metabolism of clopidogrel is catalyzed by several cytochrome P450 (CYP) isoforms, including CYP2C19, CYP1A2, CYP2B6 and CYP3A4/5 (Clarke and Waskell, 2003; Hagihara et al., 2009; Kazui et al., 2010; Dansette et al., 2012) . The CYP2C19 loss-of-function alleles are associated with low plasma concentrations of the active metabolite and poor clopidogrel responsiveness (Hulot et al., 2006; Giusti et al., 2007; Sibbing et al., 2009; Simon et al., 2009; Hochholzer et al., 2010) . Interestingly, clopidogrel is also a mechanism-based inhibitor of CYP2C19 and CYP2B6 (Richter et al., 2004; Nishiya et al., 2009) . In healthy volunteers, pretreatment with clopidogrel significantly increased the area under the plasma concentration-time curve (AUC) of omeprazole in subjects with homozygous CYP2C19 extensive metabolizer genotype and the AUC of the CYP2B6 substrate bupropion (Turpeinen et al., 2005; Chen et al., 2009 ). The tendency to form reactive metabolites that irreversibly inactivate CYP enzymes has recently been observed also for the secondary metabolite, clopidogrel acyl-β-D-glucuronide. This glucuronide metabolite was shown to be a strong mechanism-based inhibitor of CYP2C8, leading to This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on November 14, 2017 as DOI: 10.1124 at ASPET Journals on November 24, 2017 dmd.aspetjournals.org Downloaded from DMD #78162 5 a marked increase in the plasma concentrations of repaglinide and pioglitazone (Tornio et al., 2014; Itkonen et al., 2016) .
The hydrolysis of clopidogrel into clopidogrel carboxylic acid is catalyzed by carboxylesterase 1 (CES1) (Tang et al., 2006) , as demonstrated clinically by the increased antiplatelet effects of clopidogrel in carriers of a loss-of-function single nucleotide variant of CES1 (Tarkiainen et al., 2015) . What is not known, yet, is which UGT enzymes catalyse the glucuronidation of clopidogrel carboxylic acid into clopidogrel acyl-β-D-glucuronide. Identifying the UGT enzymes responsible for this activity is particularly interesting since the metabolic pathway leads to the formation of a bioactive glucuronide metabolite that inactivates CYP2C8. To this end, we carried out an in vitro study to elucidate the role of 13 human UGTs in the formation of clopidogrel acyl-β-D-glucuronide. Moreover, to gain insight into the clinical relevance of the findings, we investigated the effects of common variants in relevant UGT genes on the pharmacokinetics of clopidogrel carboxylic acid glucuronidation in a population comprising healthy volunteers from previous and ongoing pharmacokinetic studies.
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Materials and Methods

Materials
Pooled HLM (UltraPool), pooled HIM, and microsomes from baculovirus infected insect cells expressing recombinant human UGT isoforms (Supersomes) were purchased from Corning (Corning, NY, USA), except for His-tagged UGT1A10 (UGT1A10-H) which was prepared in Helsinki as previously described (Kuuranne et al., 2003) . The rapid equilibrium dialysis device 
In Vitro Study
UGT Incubation Conditions. Human recombinant UGTs (hrUGTs), pooled human liver microsomes (HLM) or pooled human intestinal microsomes (HIM) were diluted in 0.1 M sodium phosphate buffer (pH 7.4) containing MgCl 2 (10 mM). In addition, the pore forming peptide alamethicin (10 µg· mL -1 ) was added to incubation mixtures containing HLM or HIM. The protein concentrations in hrUGT, HLM and HIM incubations ranged from 0.2 to 0.8 mg· mL -1 , as described for each assay below. Clopidogrel carboxylic acid concentration ranged from 0.5 to 3000
This article has not been copyedited and formatted. The final version may differ from this version. µM, depending on the experiment. HLM and HIM incubation mixtures were kept on ice for 20 minutes before preincubation to allow pore formation by alamethicin. For consistency, the same treatment was applied to hrUGT incubations. The incubation mixtures were then moved to a heated shaker and preincubated for 5 minutes (at 37°C, 300 rpm), followed by addition of 5 mM uridinediphosphate glucuronic acid (UDPGA) to initiate the reactions. Incubations were terminated after a designated time by mixing one part reaction mixture with three parts acetonitrile containing clopidogrel-d4 carboxylic acid as an internal standard. Samples were vortexed and cooled on ice for at least 10 minutes before centrifugation (20 800 x g for 10 min). Finally, the supernatants were transferred to HPLC microvials for LC/MS/MS analysis. The non-specific binding of 0.5 µM clopidogrel carboxylic acid to HLM (0.4 and 0.8 mg· mL -1 ) and HIM (0.2 mg· mL -1 ), 1 and 30 µM clopidogrel carboxylic acid to hrUGT2B17 (0.2 mg· mL -1 ) and 100 µM clopidogrel to HLM and HIM (0.8 mg· mL -1 ) was determined by equilibrium analysis using the rapid equilibrium dialysis method. The fraction unbound was at least 0.8 in all incubations. Substrate and inhibitor compounds were dissolved in acetonitrile and methanol, respectively. The final solvent concentrations in incubations were 1% or less. All incubations were performed in duplicates.
UGT Screening. To identify the specific UGTs responsible for clopidogrel carboxylic acid metabolism, glucuronidation was tested in human recombinant UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, His-tagged UGT1A10 (UGT1A10-H), UGT2B4, UGT2B7, UGT2B10, UGT2B15 and UGT2B17 at a final protein concentration of 0.4 mg· mL -1 . In this experiment, clopidogrel carboxylic acid (10 µM) was incubated with each UGT enzyme for 30 and 90 minutes as described above.
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Clopidogrel Carboxylic Acid Metabolism in HLM, HIM, hrUGT2B7 and hrUGT2B17. In order to determine the maximal linear range of glucuronidation, depletion of 0.5 µM clopidogrel carboxylic acid and formation of clopidogrel acyl-β-D-glucuronide were measured in HLM, HIM, and recombinant UGT2B7 and UGT2B17 (0.4 and 0.8 mg· mL -1 ) for up to 90 minutes. This clopidogrel carboxylic acid concentration is within the clinically relevant range, since its average peak plasma concentration (C max ) in the clinical data was 35 and 72 µM, corresponding to unbound concentrations (C max,u ) of 0.7 and 1.4 µM for the 300 and 600 mg dose, respectively.
Inhibition Experiments. Clopidogrel carboxylic acid glucuronidation in HLM, HIM, UGT2B7
and UGT2B17 was investigated in the absence and presence of the potential UGT2B7 inhibitors aprepitant, fluconazole, gemfibrozil, ketamine and mefenamic acid, as well as the UGT2B17 inhibitor imatinib (Uchaipichat et al., 2006; Knights et al., 2009; Uchaipichat et al., 2011; House et al., 2015; Zhang et al., 2015) . In addition, the selectivity of inhibition by gemfibrozil, mefenamic acid and imatinib was further investigated in UGT1A3, UGT1A9, UGT1A10-H and UGT2B4.
Inhibition experiments were performed using clopidogrel carboxylic acid concentration of 0.5 µM for HLM and HIM incubations (0.4 mg· mL -1 ) and 5 µM for hrUGT incubations (0.2 mg· mL -1 ).
Concentrations of aprepitant, fluconazole, gemfibrozil, ketamine, mefenamic acid and imatinib in the incubations were 10, 2500, 100, 500, 5 and 5 µM, respectively. incubating 10 µM or 100 µM clopidogrel for 90 minutes. Incubation mixtures were prepared as described for UGT incubation conditions, with the exception that UDPGA was added to the mixture before preincubation and the reaction was initiated by the addition of the substrate.
Clopidogrel Carboxylic Acid Metabolism and CYP2C8 Inhibition in HLM.
The formation of clopidogrel acyl-β-D-glucuronide from clopidogrel carboxylic acid and the subsequent inactivation of CYP2C8 were studied in HLM using amodiaquine N-desethylation as a marker reaction for CYP2C8 activity. Briefly, incubation mixtures containing clopidogrel carboxylic acid (50 µM) in HLM (0.5 mg· mL -1 ) were prepared as described previously. However, after preincubation for 5 minutes, a combined cofactor solution containing both 5 mM UDPGA (to initiate glucuronidation) and 1 mM NADPH (to initiate metabolism-dependent inactivation of CYP2C8 by clopidogrel acyl-β-D-glucuronide) was added to the mixtures. At determined time points, aliquots of 7.5 µL of the reaction mixture were transferred to other tubes containing amodiaquine (10 µM) and NADPH (1 mM) in buffer in a final incubation volume of 150 µL to measure CYP2C8 activity. Protein and inhibitor concentrations were thus diluted 20-fold and direct inhibition by clopidogrel acyl-β-Dglucuronide was minimized by using an amodiaquine concentration higher than its K m for CYP2C8.
The reaction mixture was incubated for 2 minutes (37°C, 300 rpm) and the reaction was stopped by Substrate inhibition
where K i represents the dissociation constant for the inhibitory substrate-enzyme-substrate ternary complex.
Sigmoidal ( where n is the Hill coefficient.
Two binding sites
where K m1 and K m2 represent the Michaelis-Menten constants for the binding of the substrate molecules to the first and second binding site, respectively (Korzekwa et al., 1998) .
Intrinsic clearance for clopidogrel acyl-β-D-glucuronide formation (CL int ) was calculated according to CL int = V max /K m . This equation can be used for determination of CL int and reaction phenotyping when the substrate concentration is less than 10% of the K m . In our clinical study, the average C max,u was less than 10% of the lowest K m of the recombinant UGTs. Likewise, the substrate concentrations used for CL int,u,dep determination and the inhibition experiments in HLM and HIM were only 3% of the lowest K m , corresponding to the clinically relevant concentration range.
Pseudo-first-order depletion rate constants (k dep ) were determined for the depletion of 0.5 µM clopidogrel carboxylic acid in HLM and HIM using nonlinear regression analysis (SigmaPlot). The intrinsic clearance in depletion experiments was calculated as CL int , dep = k dep /[M], where [M] is the microsomal protein concentration (Venkatakrishnan et al., 2003) . The relative contributions of UGT1A3, UGT1A9, UGT2B4, UGT2B7, and UGT2B17 in the hepatic metabolism of clopidogrel carboxylic acid were estimated from the determined CL int values using a conversion factor, which was determined from previously published peptide-based quantification studies by dividing the molar abundancy of each UGT isoform in human liver microsomes with the molar abundancy of the respective hrUGT isoform in baculovirus infected insect cells (Supersomes) (Fallon et al., 2013a; Fallon et al., 2013b; Sato et al., 2014) . The relative contribution of each UGT isoform in This article has not been copyedited and formatted. The final version may differ from this version. (Houston and Galetin, 2008) and 25.7 g of liver/kg body wt. (Davies and Morris, 1993) .
Clopidogrel Pharmacokinetics and Pharmacogenetic Analysis in Healthy Volunteers
Subjects and Study Design. A total of 106 healthy Finnish volunteers from eight of our previous or ongoing pharmacokinetic studies (49 women and 57 men; mean ± S.D.: age 24 ± 4 years, height 175 ± 9 cm, weight 71 ± 13 kg, and body mass index 23 ± 3 kg/m 2 ), including six drug-drug interaction studies and two genotype panel studies, were available for pharmacogenetic analysis (Supplementary Table 1 ) (Holmberg et al., 2014; Tornio et al., 2014; Itkonen et al., 2015; Tarkiainen et al., 2015; Itkonen et al., 2016; Holmberg et al., unpublished data; Itkonen et al., unpublished data) . No individuals with a non-Caucasian background or excess relatedness were included in the study. During these studies, each subject was given a single 300 mg (n=49) or 600 mg (n=57) dose of clopidogrel in the morning after an overnight fast. Timed EDTA blood samples, including a sample for DNA extraction, were drawn before and at designated times after clopidogrel ingestion. Plasma concentrations of clopidogrel and its metabolites were quantified using LC/MS/MS, as described in the respective studies. The health of the subjects was confirmed by their medical history, physical examination, and routine laboratory tests before entering the study.
All subjects had normal blood platelet counts and haemoglobin values. None was a tobacco smoker and none used any continuous medication (e.g. oral contraceptives). A written informed consent was obtained from all study participants for participation in pharmacogenetic studies and the studies (Figure 2) . UGT1A3, UGT1A9, UGT1A10-H and UGT2B4 also showed significant activities, between 5% and 20% of the UGT2B17 rates. The glucuronidation activities of UGT1A4, UGT1A6, UGT1A7 and UGT2B15
were very low or negligible and these enzymes were thus excluded from detailed kinetic analyses.
UGT1A1, UGT1A8, UGT1A10 and UGT2B10 did not form any detectable clopidogrel acyl-β-Dglucuronide.
The kinetics of clopidogrel carboxylic acid glucuronidation by UGT1A3, UGT1A9, UGT2B7
and UGT2B17 followed the Michaelis-Menten model (Figure 3) . For UGT1A10-H, several kinetic models gave a reasonable fit, and the Michaelis-Menten model was chosen based on confidence level in the parameter estimates. Clopidrogel carboxylic acid glucuronidation by UGT2B4 displayed non-hyperbolic kinetics and the best fit was obtained with the two binding sites model.
The calculated kinetic parameters, including parameters that are not shown in Figure 3 , are summarized in Table 1 .
To allow estimation of the clinical relevance of each UGT in the metabolism of clopidogrel, we scaled the in vitro CL int,u data to the average hepatic and intestinal microsomal intrinsic clearance on the basis of published protein expression data. Despite its weaknesses, this scaling method could be used to approximate the contributions of most UGTs identified in this study. UGT2B17 and UGT2B7 exhibited the highest CL int,u values of clopidogrel carboxylic acid glucuronidation (Table   1 ). After abundancy-based scaling, UGT2B7 was estimated to have the highest unbound intrinsic liver microsomal clearance (CL int,u,HLM ), accounting for about 55-60% of the total (combined) intrinsic clearance (CL int,u,HLM,tot ). UGT2B7 was followed by UGT1A9, UGT2B4 and UGT2B17, Table 2) .
Inhibition of Clopidogrel Carboxylic Acid Glucuronidation by Chemical Inhibitors of UGTs.
In preliminary experiments in hrUGT2B7 and hrUGT2B17, aprepitant (10 µM), fluconazole (2.5 mM) and ketamine (500 µM) inhibited both UGT2B7 and UGT2B17-mediated clopidogrel carboxylic acid glucuronidation by >90% ( Figure 4A ). Gemfibrozil (100 µM) showed very strong UGT2B7 inhibition (100%), but also moderate inhibition (30-70%) of other UGTs, including UGT1A9, UGT1A10-H, UGT2B4 and UGT2B17 ( Figure 4B ). Mefenamic acid (5 µM) had a strong inhibitory effect on both UGT2B7 (95%) and UGT1A9 (98%), but no inhibitory effect on UGT1A3, UGT2B4 and UGT2B17. In contrast, 5 µM imatinib strongly and selectively inhibited UGT2B17 activity (100% inhibition), with only a small inhibitory effect on UGT2B7 (16% inhibition) and a moderate effect on UGT1A10-H (59%). 
Discussion
In the present study, we investigated the glucuronidation of clopidogrel carboxylic acid in vitro, and assessed the relative contributions of the different UGT enzymes to clopidogrel acyl-β-Dglucuronide formation by using two in vitro approaches. Both an approach with chemical UGT inhibitors in HLMs and a scaling approach of recombinant UGT mediated clearances using peptidebased quantification data from previous publications (Fallon et al., 2013a; Fallon et al., 2013b; Sato et al., 2014) were consistent with an important role of UGT2B7 and UGT2B17 in the glucuronidation of clopidogrel carboxylic acid. In addition, UGT1A3, UGT1A9, UGT1A10-H and particularly UGT2B4 were estimated to participate in clopidogrel carboxylic acid glucuronidation.
The role of UGT2B17 could also be verified in a clinical pharmacogenetic study.
Fluconazole and ketamine strongly inhibit UGT2B4, UGT2B7 and UGT2B17, with only minor effects on other relevant UGTs (Uchaipichat et al., 2006; Raungrut et al., 2010; Uchaipichat et al., 2011; House et al., 2015) . In HLM, they reduced clopidogrel carboxylic acid glucuronidation by up to 90%, suggesting that collectively, UGT2B4, UGT2B7 and UGT2B17 are responsible for the majority of clopidogrel acyl-β-D-glucuronide formation in the liver. Furthermore, the nonselective UGT2B7 inhibitors mefenamic acid and gemfibrozil inhibited clopidogrel carboxylic acid glucuronidation in HLM by about 40%. Accordingly, UGT2B7 is likely to play a large role in the formation of clopidogrel acyl-β-D-glucuronide in the liver. On the other hand, the UGT2B17 inhibitor imatinib had practically no effect on clopidogrel carboxylic acid glucuronidation, suggesting a very small role for UGT2B17 in the liver.
In the liver, UGT2B7, UGT2B4 and UGT1A9 are relatively abundant, whereas the expression of UGT2B17 is low (Oda et al., 2012; Achour et al., 2014; Sato et al., 2014) . Consequently, the abundancy-based scaling suggested that UGT2B7 accounts for almost 60% of the total unbound hepatic microsomal intrinsic clearance of clopidogrel carboxylic acid, while particularly UGT2B4, UGT2B17, UGT2B7 and UGT1A10 are expressed in the intestinal wall, but most other relevant UGTs are virtually absent (Sato et al., 2014) . The strong (85%) inhibition of clopidogrel acyl-β-D-glucuronide formation by the UGT2B17 inhibitor imatinib in HIM indicates that UGT2B17 is mostly responsible for clopidogrel carboxylic acid metabolism in the intestinal wall.
Since UGT1A9 is only minimally expressed in enterocytes (Oda et al., 2012) , the minor (12%) inhibition by the UGT2B7 and UGT1A9 inhibitor mefenamic acid in HIM suggests that also UGT2B7 has a small role. In excellent agreement, the scaling approach estimated a major role for UGT2B17 in the unbound intestinal intrinsic clearance, UGT2B7 having a less significant role. In addition to these UGT2B enzymes, UGT1A10 may slightly contribute to the metabolism of clopidogrel carboxylic acid in the intestinal wall, since imatinib weakly inhibits UGT1A10 and the scaling suggested a minimal role for UGT1A10 in the CL int,u,HIM,tot .
Analysis of clinical data provided the final approach to investigate the contributions of UGT2B7 and UGT2B17 to the glucuronidation of clopidogrel carboxylic acid. No statistically significant associations between UGT2B7 variants and clopidogrel pharmacokinetics; were observed. However, the common UGT2B7*2 allele has rarely had any effect on the glucuronidation kinetics of UGT2B7 substrates and is thought to have little impact on enzyme activity (Bhasker et al., 2000; Peterkin et al., 2007; Parmar et al., 2011; Rae et al., 2012) . Therefore, the clinical data do not allow direct estimation of the contribution of UGT2B7 to clopidogrel metabolism.
In contrast to UGT2B7, there is a common deletion in the UGT2B17 gene, which leads to complete UGT2B17 deficiency (Murata et al., 2003) . The absence of UGT2B17 due to homozygous deletion of the UGT2B17 gene is common in Caucasian and African populations (~10-40%) and very frequent in East Asia (up to ~90%) (Wilson et al., 2004; Jakobsson et al., 2006; Xue et al., 2008; Chen et al., 2010; Giroux et al., 2012) . As expected, the UGT2B17 deletion was common in our Finnish population, with an allele frequency of 45%. Moreover, clopidogrel acyl-β-Dglucuronide formation was impaired in carriers of the deletion, leading to a 10% or 19% lower clopidogrel acyl-β-D-glucuronide to clopidogrel carboxylic acid plasma AUC 0-4 ratio in heterozygous and homozygous carriers, respectively, than in individuals carrying two functional copies of UGT2B17. Given that homozygous carriers of the deletion lack any metabolic activity by UGT2B17, the results suggest that the combined contribution of intestinal and hepatic UGT2B17 to clopidogrel carboxylic acid glucuronidation is about 10% in heterozygous carriers and 20% in noncarriers, leaving 90% or 80% to other UGTs, respectively. As the in vitro findings indicate that UGT2B17 is largely responsible for clopidogrel carboxylic acid glucuronidation in the intestinal wall, with about 10% contribution in the liver, it could be estimated that up to about 10% of clopidogrel acyl-β-D-glucuronide is formed in the intestine, depending on UGT2B17 genotype.
Moreover, as both clopidogrel carboxylic acid and acyl-β-D-glucuronide were formed from clopidogrel in HIM, there seems to be an interplay of CES1 and UGT2B17 in the intestinal wall.
CYPs and UGTs are located intracellularly on opposite sides of the endoplasmic membranes and there is evidence for a protein-protein interplay between certain UGT and CYP enzymes (Takeda et al., 2005; Ishii et al., 2010; Miyauchi et al., 2015) . This interplay and the close proximity 
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CYP2C8. Such a mechanism might also partially explain why the clopidogrel-repaglinide interaction was best predicted, when the unbound concentration of clopidogrel acyl-β-Dglucuronide was assumed to be almost 20 times higher in hepatocytes than in plasma (Tornio et al., 2014 ).
In conclusion, the present study indicates that UGT2B7 is the main enzyme involved in clopidogrel carboxylic acid glucuronidation in the liver, while at least UGT2B4, and possibly also This article has not been copyedited and formatted. The final version may differ from this version. Tables   Table 1. Kinetic parameters (mean ± S.D.) of clopidogrel carboxylic acid glucuronidation by UGT1A3, UGT1A9, UGT1A10-H, UGT2B4, UGT2B7 and UGT2B17 and scaling of their contributions to the total microsomal intrinsic clearance in the liver and intestine.
a Scaling of intrinsic clearance values was calculated using UGT abundancies in the liver and intestine published by Sato et al. (2014) . b Scaling of intrinsic clearance values was calculated using UGT abundancies in the liver published by Fallon et al. (2013a; 2013b) 
